[Dermatologic side effects induced by new angiogenesis inhibitors]

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Targeted anticancer therapies often possess antiangiogenic activity.
• These drugs target signaling pathways and receptors crucial for skin and hair follicle physiology.
• Cutaneous toxicity is a significant concern with these novel agents.

Purpose of the Study:

• To review the primary dermatologic adverse events associated with antiangiogenic targeted therapies.
• To provide an overview of skin and hair-related toxicities induced by specific anticancer drugs.

Main Methods:

• Literature review of dermatologic adverse events.
• Analysis of side effect profiles for key antiangiogenic drugs.
• Synthesis of information on cutaneous toxicities.

Main Results:

• Common dermatologic adverse events include rash, hand-foot syndrome, and hair changes.
• Specific drugs like sorafenib, sunitinib, pazopanib, vandetanib, everolimus, temsirolimus, and bevacizumab are associated with distinct cutaneous toxicities.
• The physiological expression of targeted pathways in the skin contributes to these side effects.

Conclusions:

• Antiangiogenic targeted therapies, despite a favorable safety profile, frequently cause dermatologic adverse events.
• Understanding and managing these cutaneous toxicities is essential for patient care.
• Further research into mitigating these side effects is warranted.